SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is seeing intense market activity as investors weigh the strategic implications of its acquisition of Boeing's autonomous flight assets, including Wisk Aero and Insitu, against concerns over share dilution. While the community is deeply divided between long-term bulls highlighting potential defense-sector synergies and skeptics questioning the company's timeline for achieving piloted transition, trading volume has surged ahead of the upcoming earnings call.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is trending following positive Phase 2 clinical results for its ABCL635 candidate, which demonstrated best-in-class efficacy for treating vasomotor symptoms. The community is actively discussing how this readout serves as a critical proof-of-concept for the company's proprietary GPCR discovery platform and internal drug pipeline, fueling bullish sentiment despite intense short-term volatility.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending after reporting a major earnings beat with record revenue and a multi-year supply agreement with Lumentum that solidified its role in the optical AI infrastructure supply chain. Investors are actively debating the company's long-term growth potential in high-speed data networking versus risks related to its manufacturing footprint and high short interest.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings ($LITE) is trending as investors debate whether recent volatility in the photonics sector represents a healthy reset in a long-term AI infrastructure growth trend or a deeper fundamental shift. While some community members are concerned by heavy institutional selling and technical weakness, bullish voices emphasize Lumentum's strategic importance in the optical networking bottleneck as hyperscalers continue expanding data center capacity.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending following a significant volatility event and analyst upgrades, with the community actively debating whether the recent sharp pullback represents a structural breakdown or a temporary overreaction. Traders are focused on potential gap-fill setups and the company's long-term pivot toward edge computing and AI-driven security services.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is currently trending as a top performer in the software sector, with investors closely watching its role as a critical component in the AI and observability stack. The community is actively debating its valuation compared to peers and focusing on its recent revenue growth, with many discussing its potential to benefit from enterprise-wide AI adoption.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is seeing heightened activity as market participants closely monitor the Federal Reserve's interest rate trajectory and broader economic data for signs of a potential shift toward monetary easing. Investors are actively debating the metal's role as a hedge against fiat currency devaluation, with many focusing on whether recent technical consolidation signals a definitive breakout or continued volatility ahead.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as investors gear up for a pivotal earnings report, with the community intensely debating whether the companys massive backlog and AI infrastructure demand can overcome governance concerns and financing pressures. Bulls are focused on a potential valuation reset driven by strong revenue and margin growth, while bears remain skeptical, citing past regulatory controversies and the potential for further share dilution.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is facing significant downward pressure and intense retail backlash following a large public offering priced at a discount to market value. Community discussions are heavily focused on the company's high cash burn, recurring dilution, and skepticism toward executive leadership, as investors weigh the potential of its CGM technology against ongoing financial volatility.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors monitor it alongside broader cybersecurity sector leaders, with the community closely analyzing its resilience platform and potential for AI-driven growth ahead of upcoming earnings. Discussions are centered on the company's competitive standing, institutional accumulation, and the ongoing debate over whether software stocks will experience a sustained breakout or face continued volatility due to broader market correlations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.

Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion 

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.

Company News for July 13, 2026

Companies In The Article Are:WDFC,DAL,NRIX and FCX

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -10.96% and -36.76%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug 

RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.

Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.59	--	--	N/A
Q2 '26	-$0.72	-$0.81	-12.05%	MISSED
Q1 '26	-$0.76	-$0.79	-3.60%	MISSED
Q4 '25	-$0.87	-$0.82	5.85%	BEAT
Q3 '25	-$0.82	-$1.03	-26.01%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '26

Historical Earnings